Cancer heterogeneity is not compatible with one unique cancer cell metabolic map

The Warburg effect and its accompanying metabolic features (anaplerosis, cataplerosis) are presented in textbooks and reviews as a hallmark (general characteristic): the metabolic map of cancer. On the other hand, research articles on specific tumors since a few years emphasize various biological fe...

Full description

Saved in:
Bibliographic Details
Published in:Oncogene 2017-05, Vol.36 (19), p.2637-2642
Main Authors: Strickaert, A, Saiselet, M, Dom, G, De Deken, X, Dumont, J E, Feron, O, Sonveaux, P, Maenhaut, C
Format: Article
Language:English
Subjects:
631/67/2327
Apoptosis
Cancer
Cancer cells
Cancer research
Cell Biology
Cell metabolism
Epithelial-Mesenchymal Transition - genetics
Genetic Heterogeneity
Glycolysis
Health aspects
Human Genetics
Humans
Internal Medicine
Medicine
Medicine & Public Health
Metabolic Networks and Pathways - genetics
Metabolism
Neoplasms - genetics
Neoplasms - metabolism
Oncology
Review
Tumorigenesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Warburg effect and its accompanying metabolic features (anaplerosis, cataplerosis) are presented in textbooks and reviews as a hallmark (general characteristic): the metabolic map of cancer. On the other hand, research articles on specific tumors since a few years emphasize various biological features of different cancers, different cells in a cancer and the dynamic heterogeneity of these cells. We have analysed the research literature of the subject and show the generality of a dynamic, evolving biological and metabolic, spatial and temporal heterogeneity of individual cancers. We conclude that there is no one metabolic map of cancer but several and describe the two extremes of a panel from the hypoxic to the normoxic state. The implications for the significance of general ‘omic’ studies, and on therapeutic conclusions drawn from them and for the diagnostic use of fractional biopsies is discussed.
ISSN:0950-9232
1476-5594
DOI:10.1038/onc.2016.411